Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RSNA In Brief

This article was originally published in The Gray Sheet

Executive Summary

GE/Amersham Health: Firms' research agreement inked Nov. 27 will focus initially on radiopharmaceuticals to be used with positron emission tomography (PET) in diagnosis of Parkinson's disease. FDG and FDOPA are among pharmaceuticals under study. GE Medical Systems also announces FDA approval for its sixteen-slice PET system, to be launched in the U.S. next year...

You may also be interested in...



R2 $86 Mil. Offering Would Fund LungCheck CAD Software Development

R2 Technologies' proposed initial public offering will fund development of the LungCheck computer-aided detection (CAD) system for screening abnormalities in chest computerized tomography (CT) scans, and shore up its current mammography CAD business

R2 $86 Mil. Offering Would Fund LungCheck CAD Software Development

R2 Technologies' proposed initial public offering will fund development of the LungCheck computer-aided detection (CAD) system for screening abnormalities in chest computerized tomography (CT) scans, and shore up its current mammography CAD business

Fischer Taking Chance With SenoScan 510(k), Leaving PMA Route Open

Fischer Imaging's premarket notification submission for the SenoScan full-field digital mammography system is readily convertible into a PMA, should FDA reject the 510(k) approach for the device, as the agency has done in the past.

Related Content

UsernamePublicRestriction

Register

MT015791

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel